Items tagged with Drug-resistant TB
Indian government negotiating with firms for better access to new TB drugs (post)
The government wants Johnson & Johnson and Mylan to provide treatment for multidrug-resistant TB patients as part of the Revised National Tuberculosis Control Programme.
J&J, Macleods in talks for license deal of TB drug (post)
Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson (J&J) are in talks for a voluntary license deal for the TB drug bedaquiline.
Janssen Pharmaceutica to expand production of Sirturo in Russia (post)
Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson, plans to increase production of its Sirturo (bedaquiline) – an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reports The Pharma Letter’s local correspondent.
A day in the life of India's 'TB warrior' (post)
On World TB Day, public health specialist Chapal Mehra describes the work of Dr Zarir Udwadia, who has been working tirelessly to fight the disease in its often untreatable forms.
A fourth of Indian TB patients are drug-resistant (post)
The first-ever survey of drug-resistant tuberculosis (DR-TB) has found that over a quarter of patients in India could be resistant to one or more drugs that can cure them. India is home to 2.8 million TB patients, the largest in the world.
Otsuka's DELTYBA approved in China for the treatment of multidrug-resistant TB (post)
Otsuka Pharmaceutical Co., Ltd. announces that on March 12, DELTYBA® Tablets 50 mg (generic name: delamanid) received regulatory approval by the China Food and Drug Administration. Approval was granted for the manufacture and marketing of DELTYBA as a treatment for multidrug-resistant, pulmonary tuberculosis (MDR-TB) in adults.
RESIST-TB webinar: Combined use of delamanid and bedaquiline (post)
RESIST-TB will host a webinar about the current evidence and practices for the combined use of delamanid and bedaquiline for the treatment of multidrug-resistant TB (MDR-TB) on 5 April 2018.
Sentinel Project: March 2018 update (post)
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis released its March newsletter with many important updates, including that pediatric formulations of second-line TB drugs are now available.
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant TB (post)
SETTING
Study on drug-resistant TB patients in India: Elderly TB patients with diabetes suffer higher adverse effects from medications (post)
The International Conference on Harmonization considers older people a “special population as they differ from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics and greater vulnerability to adverse drug reactions”.
Page 49 of 117 · Total posts: 0
←First 48 49 50 Last→